Home / Health/ Coronavirus: Remdesivir’s failure is a caution for Covid-19 vaccines
As my colleague Max Nisen just recently observed, it’s perplexing that the FDA offered official approval to remdesivir as a Covid-19 treatment in October.
Healthcare facilities have been less passionate and have been sharply cutting back their use of remdesivir due to its expense and its value for only the most seriously ill patients– which makes the FDA’s enthusiasm for the drug and its producer all the more curious.
Perhaps it was just fine that the FDA relied on what was essentially an internal trial to approve remdesivir and that Hahn has been unusually amenable to Trump’s demands for authorizing questionable Covid-19 treatments.
Comments
Post a Comment